| Psoriasis vulgaris

Inflectra vs Tazorac

Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.

Deep comparison between: Inflectra vs Tazorac with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTazorac has a higher rate of injection site reactions vs Inflectra based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tazorac but not Inflectra, including UnitedHealthcare

Category

Inflectra

Tazorac

At A Glance

RouteIV infusion

FrequencyEvery 6-8 weeks

ClassTNF-alpha antagonist

RouteTopical

FrequencyDaily

ClassRetinoid

Indications

Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing spondylitis
Arthritis, Psoriatic
Psoriasis vulgaris

Psoriasis vulgaris
Acne Vulgaris

Dosing

Crohn's Disease, Ulcerative Colitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks; regimen applies to adult and pediatric patients >= 6 years.

Rheumatoid Arthritis 3 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks in combination with methotrexate; may increase up to 10 mg/kg every 8 weeks or as often as every 4 weeks for incomplete response.

Ankylosing spondylitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 6 weeks.

Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.

Psoriasis vulgaris Apply a thin film (2 mg/cm2) of 0.05% cream once daily in the evening to psoriatic lesions only; increase to 0.1% if tolerated and medically indicated.

Acne Vulgaris Apply a thin layer (2 mg/cm2) of 0.1% cream once daily in the evening to affected facial skin areas after gentle cleansing and drying.

Contraindications

Doses >5 mg/kg in patients with moderate or severe heart failure
Previous severe hypersensitivity reaction to infliximab products, inactive ingredients of INFLECTRA, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)

Pregnancy (retinoids may cause fetal harm)
Known hypersensitivity to any component of TAZORAC Cream

Drug Interactions

1225View drug interactions

201View drug interactions

Adverse Reactions

Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain

Serious Serious infections (pneumonia, cellulitis, abscess, sepsis, tuberculosis, opportunistic infections), malignancies, lymphoma, hepatotoxicity (acute liver failure, autoimmune hepatitis), severe infusion reactions, lupus-like syndrome

Postmarketing Agranulocytosis, neutropenia, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders (Guillain-Barre syndrome), acute liver failure, anaphylactic shock, cerebrovascular accidents, leukemia, melanoma, Merkel cell carcinoma

Most common (>=10%) Psoriasis: pruritus, erythema, burning; Acne: desquamation, dry skin, erythema, burning sensation

Serious Embryofetal toxicity, photosensitivity and risk of sunburn

Postmarketing Blister, dermatitis, urticaria, skin exfoliation, skin discoloration (hyperpigmentation or hypopigmentation), swelling at or near application sites, pain

Pharmacology

Infliximab-dyyb is a chimeric IgG1kappa monoclonal antibody TNF-alpha antagonist that neutralizes the biological activity of TNFalpha by binding with high affinity to soluble and transmembrane forms of TNFalpha, inhibiting receptor binding and downstream proinflammatory cytokine activity in RA, CD, UC, AS, PsA, and Ps.

Tazarotene is a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds retinoic acid receptors RAR-beta and RAR-gamma with relative selectivity and may modify gene expression in psoriatic and acne-affected skin.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Inflectra